CamGene Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Early Stage VC
- Investors
-
9
CamGene General Information
Description
Developer of nanoparticle-based mRNA therapeutic drugs designed for patients who have lost their hearing. The company's lipid nanoparticle-based mRNA technology precisely targets ear cells to deliver therapeutic proteins for the regeneration and protection of key cells in the cochlea, all at a cost that will make it feasible to create an accessible mass-market medicine, enabling doctors to treat the underlying cellular dysfunction, which is the root cause of hearing loss.
Contact Information
Website
www.camgenetx.comCorporate Office
- Hauxton House Mill
- Scitech Park Mill Lane, Hauxton
- Cambridge CB22 5HX
- England, United Kingdom
Corporate Office
- Hauxton House Mill
- Scitech Park Mill Lane, Hauxton
- Cambridge CB22 5HX
- England, United Kingdom
CamGene Timeline
CamGene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-Mar-2026 | Completed | Generating Revenue | |||
| 2. Seed Round | 29-Oct-2025 | Completed | Generating Revenue | |||
| 1. Seed Round | 02-Feb-2024 | $127K | $127K | Completed | Generating Revenue |
CamGene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Ordinary | 320,000 | $0.000134 | $0.42 | $0.42 | 1x | $0.42 | 13.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CamGene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CamGene Patents
CamGene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202503984-D0 | Mrna therapeutic composition and method of preparation thereof to enhance auditory nerve cell function | Pending | 19-Mar-2025 |
CamGene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CamGene Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cambridge Angels | Angel Group | Minority | ||
| Future Planet Capital | Venture Capital | Minority | ||
| Cambridge Enterprise Ventures | Venture Capital | Minority | ||
| Eos Advisory | Venture Capital | Minority | ||
| Hextwo Capital | Venture Capital | Minority |
CamGene FAQs
-
When was CamGene founded?
CamGene was founded in 2023.
-
Where is CamGene headquartered?
CamGene is headquartered in Cambridge, United Kingdom.
-
What is the size of CamGene?
CamGene has 8 total employees.
-
What industry is CamGene in?
CamGene’s primary industry is Biotechnology.
-
Is CamGene a private or public company?
CamGene is a Private company.
-
What is CamGene’s current revenue?
The current revenue for CamGene is .
-
How much funding has CamGene raised over time?
CamGene has raised $4.94M.
-
Who are CamGene’s investors?
Cambridge Angels, Future Planet Capital, Cambridge Enterprise Ventures, Eos Advisory, and Hextwo Capital are 5 of 9 investors who have invested in CamGene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
